Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials

Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly T, Morrow L, Hompesch M, Hellerstein M K, Li K, Johansson L, Kelly PF


Diabetes Obes Metab . 2021 Mar;23(3):700-710. doi: 10.1111/dom.14272.

View abstract Share on Linkedin Share on Twitter